Noticias y Actividades de Rebiotix
Ejecutivos
Ver el organigrama con sus 7 ejecutivos principales
Biografías más buscadas en Rebiotix
- Greg Fluet, Chief Operating Officer and Site Head
- Tom Willard, Vice President of Upstream Marketing and Market Strat...
- Lindy Bancke, Head of Clinical Development
Crear su alerta
para seguir los movimientos de los ejecutivos en Rebiotix.
Biotecnología
Rebiotix tiene 2.350 competidores entre los que se incluyen Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) y Lonza (Suiza).
Popular M&A news in Biotecnología
- Eli Lilly has announced the acquisition of Verve Therapeutics (publicado el 17 de junio de 2025).
- Sirius Therapeutics acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 16 de junio de 2025).
- BioNTech has announced the acquisition of CureVac (publicado el 12 de junio de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Rebiotix
- Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic - Ferring Pharmaceuticals USA
- Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
- Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic
- Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022 - Ferring Pharmaceuticals USA
- Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022 - Ferring Pharmaceuticals USA
- Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
- Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
- Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
- Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
- Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020 - Rebiotix
- View more press releases Close
Redes sociales sobre Rebiotix
- Rebiotix en Wikipedia, Google News y Yahoo Finance
- Rebiotix en LinkedIn, Twitter y YouTube
